Get in touch

Assay development for drug development and translational research

Research programs often slow down or fail when the assays used to study a target, pathway, or biomarker are not robust enough to support confident decision-making.

In translational and preclinical settings, the issue is not only if signal can be measured, but whether the assay is rigorous, reproducible, and fit for its intended use. NIH and NCATS guidance place strong emphasis on rigor, reproducibility, and robust assay development in early translational research and drug discovery.

Let's discuss your assay strategy

Whom we serve

Our service is for biotech teams, translational research groups, pharma R&D teams, and academic investigators moving from biological insight to decision-ready experimentation.

What we solve

  • Unclear assay suitability
  • Poor reproducibility
  • Uncertainty around screening capabilities
  • Limited translational relevance
  • Weak signal behavior

When you need it

  • Before high-throughput screening
  • Before preclinical validation
  • Moving findings into measurable systems
  • When existing assays underperform

Our teams design, optimize, assess, and validate assay systems so that the resulting data are robust, interpretable, and aligned with the biological question being asked.

Based on experience in translational research and work with biotech, pharma, and academic research teams, we support scientists in designing, optimizing, and validating assays that generate robust, interpretable, biologically meaningful, and most importantly actionable data.

Kris Nys

Managing director Discovery Studio

Our work is aligned with translational research and drug development standards, where assay rigor and fitness for purpose are essential before advancing to screening, proof-of-concept, or broader validation studies.

When is assay development critical?

Assay development is critical for key decision points in drug discovery and translational research, particularly when data quality and relevance directly impacts downstream decisions and outcomes.
You may need assay development support in the following situations:
  • Before starting high-throughput screening campaigns
  • When assays show poor reproducibility

    Or inconsistent signal behavior

  • When assays show poor reproducibility

    Or functional assays linked to specific biological mechanisms

  • When translating basic research findings

    Into measurable and repeatable assay systems

  • When preparing preclinical validation experiments
  • When the current model may not be suitable

    For the scientific question or intended use

These are the points at which assay weaknesses become expensive in scientific terms. A method that is only partially characterized can introduce biased outcomes, false positives, false negatives, unstable decision thresholds, or biological interpretations that do not hold when the work is expanded across plates, runs, analysts, or study stages.
Early recognition of these scenarios helps reduce experimental risk and supports more reliable research outcomes.
Let's discuss your assay strategy

When is assay development critical?

Assay development is critical for key decision points in drug discovery and translational research, particularly when data quality and relevance directly impacts downstream decisions and outcomes.

Biological relevance of the assay

We assess if the assay truly reflects the biological mechanism, pathway, or hypothesis it is intended to measure. In translational research, assay design should be tied to a clearly defined biological question and intended use rather than signal generation alone.

Assay robustness and reproducibility

We evaluate signal behavior, variability, reproducibility, and the ability of the assay to perform consistently under defined conditions. Reproducibility across runs, operators, and experimental setups is critical to ensure that observed effects are consistent and not driven by technical variability.

Model and system suitability

The choice of experimental system — whether cell-based, biochemical, or organism-level — can directly impact assay performance. Evaluation focuses on whether the selected model appropriately represents the biological context required for drug discovery or translational research objectives.

Detection technologies and readouts

Selection of detection methods and assay platforms influences sensitivity, specificity, and scalability. Analytical approaches must align with the assay’s purpose, so that the readouts generated are reliable, quantifiable, and suitable for downstream applications.
Let's discuss your assay strategy

How our assay development process works

Drug discovery and translational research assays are developed through rigorous framework to ensure clarity, relevance, and experimental reliability at each stage.

Scientific intake and objective definition

We begin by defining the biological question, target context, experimental constraints, and intended use of the assay. It ensures the work is aligned with the scientific decision the assay needs to support.

Assay design and feasibility assessment

We assess the assay format, biological model, detection strategy, and practical feasibility of implementation. The aim is to select an approach that is both scientifically appropriate and technically defensible.

Optimization and validation

Assay conditions are systematically refined to improve signal quality, reduce variability, and ensure reproducibility. Validation focuses on confirming that the assay performs consistently across different conditions and use cases.

Strategic recommendations

We provide scientific recommendations on how the assay should be used in screening, preclinical validation, biomarker development, or broader translational workflows. Our goal is to develop assays that generate reliable, reproducible, and biologically meaningful data.

Let's discuss your assay strategy

What robust assay development enables

Robust assay development improves the quality of scientific decisions rather than merely producing a report. When assay systems are biologically relevant, analytically suitable, and reproducible, teams can interpret results with greater confidence and reduce the risk of building later work on unstable measurements.

More reliable experimental data

For drug discovery and translational decisions

Reduced risk of misleading results

Fewer false positives, false negatives, or misleading readouts

Stronger biological validation

Of targets, mechanisms, and biomarkers

Better prioritization

Of research programs and follow-up experiments

Improved readiness

For screening, proof-of-concept work, or broader translational studies

How assay development fits into the broader research workflow

Assay development should be understood as part of a broader research workflow, not as an isolated technical task. In many programs it sits between early target or mechanism work and downstream activities such as therapeutic relevance assessment, proof-of-concept validation, program prioritization, and molecular indication selection or patient stratification.

Translational science is an interconnected spectrum in which each stage informs the others. That framing is useful here because assay quality affects not only the immediate experiment but also the reliability of later decisions built on the resulting data.

Who we typically support

Academic research groups

Translating discoveries into measurable assays

Biotech startups

Preparing drug discovery or biomarker programs

Translational research teams

Building assay systems around specific biological questions

Research teams preparing screening or validation experiments

Where assay suitability must be clarified before larger studies begin

Pharma R&D groups

Exploring new targets, pathways, or functional mechanisms
Let's discuss your assay strategy

Discuss your assay
strategy

If you are developing a new assay, evaluating an existing assay system, or deciding whether a current method is robust enough for downstream work, we offer non-binding scientific discussions focused on assay strategy.

These discussions are intended to clarify the biological objective, assay suitability, validation priorities, and the degree of confidence the method can realistically support.

Frequently asked questions

What is assay development in drug discovery?
Assay development is the process of designing, optimizing, and validating an experimental method so it can measure a biological activity, target, pathway, phenotype, or biomarker in a way that is suitable for the intended research or development use. Fit-for-purpose assay development is a core part of early-stage drug discovery.
Validation matters because teams make decisions based on assay data. If performance characteristics such as reproducibility, precision, stability, or suitability are not understood, the resulting conclusions may be unreliable.
Depending on the biological question, assay development may involve biochemical assays, cell-based assays, ligand-binding assays, functional assays, imaging-based assays, immunoassays, or biomarker-linked measurements. The appropriate format depends on mechanism, sample type, readout requirements, and intended use.
Yes. In some cases, an existing assay can be improved by adjusting controls, reagents, readouts, operating conditions, or validation strategy. In other cases, if the biology, model, or analytical framework is fundamentally misaligned with the intended use, redesign is more appropriate.
There is no single standard timeline. The time required depends on the complexity of the biology, the maturity of the starting method, the performance requirements, and whether the assay must be optimized, partially validated, or fully validated for a specific use.
Teams optimize assay conditions, include appropriate controls, and use secondary or counter-assays to confirm results. It reduces the risk of advancing misleading data in drug discovery workflows.
Reproducibility is ensured by controlling experimental conditions, applying validated protocols, and using reference standards. Performance is tested across multiple runs and operators, while signal strength, variability, and dynamic range are systematically evaluated.
Assay development should begin before critical downstream decisions depend on the readout, particularly before screening campaigns, preclinical validation studies, or biomarker-driven decision points. Starting earlier reduces the risk of committing resources to data generated by a method that is not yet biologically or analytically fit for purpose.